(Q39084331)

8 September 2017

Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective (English)

1 reference

8 September 2017

0 references

1 reference

4

Peter Carmeliet

1 reference

8 September 2017

Rindert Missiaen

1

1 reference

PubMed ID

28082117

8 September 2017

Francisco Morales-Rodriguez

series ordinal

2

1 reference

PubMed ID

28082117

8 September 2017

Guy Eelen

series ordinal

3

1 reference

8 September 2017

7 January 2017

1 reference

8 September 2017

Vascular Pharmacology

1 reference

8 September 2017

90

1 reference

8 September 2017

8-18

1 reference

Hallmarks of Cancer: The Next Generation

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Developmental and pathological angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Endothelial cell metabolism: parallels and divergences with cancer cell metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

VEGF-targeted therapy: mechanisms of anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Modes of resistance to anti-angiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Role of PFKFB3-driven glycolysis in vessel sprouting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Fatty acid carbon is essential for dNTP synthesis in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Role of endothelial cell metabolism in vessel sprouting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inflammation and oxidative stress in angiogenesis and vascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Extracellular matrix, inflammation, and the angiogenic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Tumorigenesis and the angiogenic switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Angiogenesis during exercise and training

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Regulation of angiogenesis by oxygen and metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Molecular mechanisms and clinical applications of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Angiogenesis: a team effort coordinated by notch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

VEGF and Notch in tip and stalk cell selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Pericytes: blood-brain barrier safeguards against neurodegeneration?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Understanding the Warburg effect: the metabolic requirements of cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Energy turnover of vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Carbon monoxide shifts energetic metabolism from glycolysis to oxidative phosphorylation in endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Metabolism of exogenous substrates by coronary endothelial cells in culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Metabolic flux and the regulation of mammalian cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Why do cancers have high aerobic glycolysis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

A local glucose-and oxygen concentration-based insulin secretion model for pancreatic islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Mechanisms of endothelial cell migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The lamellipodium: where motility begins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Antiangiogenic activity of 2-deoxy-D-glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Anticancer agents that counteract tumor glycolysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Tumor glycolysis as a target for cancer therapy: progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Targeting metabolic transformation for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Adapting glycolysis to cancer cell proliferation: the MAPK pathway focuses on PFKFB3: Figure 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

PFKFB3 activation in cancer cells by the p38/MK2 pathway in response to stress stimuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Endothelial PFKFB3 plays a critical role in angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Regulation of NADPH-dependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma cells by a photoactive NADPH analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Quantitative flux analysis reveals folate-dependent NADPH production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Aerobic glycolysis: meeting the metabolic requirements of cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Metabolic properties of freshly isolated bovine endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Acute Activation of Oxidative Pentose Phosphate Pathway as First-Line Response to Oxidative Stress in Human Skin Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

6-Aminonicotinamide inhibition of the pentose phosphate pathway in rat neocortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of NADPH supply by 6-aminonicotinamide: effect on glutathione, nitric oxide and superoxide in J774 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Clinical use of 6-aminonicotinamide in patients with disseminated neoplastic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Site-specific O-glucosylation of the epidermal growth factor-like (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Fringe glycosyltransferases differentially modulate Notch1 proteolysis induced by Delta1 and Jagged1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Mitochondrial dysfunction and complications associated with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Integrative physiology of human adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Skeletal muscle fat oxidation: timing and flexibility are everything

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Malonyl-CoA: the regulator of fatty acid synthesis and oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Regulation and limitations to fatty acid oxidation during exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Fatty acid transport across the cell membrane: regulation by fatty acid transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Rapid Flip-flop of Oleic Acid across the Plasma Membrane of Adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Aspects of fatty acid metabolism in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Pyruvate carboxylase is required for glutamine-independent growth of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Lipid catabolism via CPT1 as a therapeutic target for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Effect of chronic CPT-1 inhibition on myocardial ischemia-reperfusion injury (I/R) in a model of diet-induced obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Changes in myocardial substrate utilisation and protection of ischemic stressed myocardium by oxfenicine [(S)-4-hydroxyphenylglycine]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Ranolazine for the treatment of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Fatty acid synthase as a potential therapeutic target in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Cellular fatty acid metabolism and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Cohort study of fatty acid synthase expression and patient survival in colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Lipid desaturation - the next step in targeting lipogenesis in cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Vascular nitric oxide: Beyond eNOS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Nitric Oxide as a Unique Bioactive Signaling Messenger in Physiology and Pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Premature senescence of human endothelial cells induced by inhibition of glutaminase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Presence of glutamine:fructose-6-phosphate amidotransferase for glucosamine-6-phosphate synthesis in endothelial cells: effects of hyperglycaemia and glutamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

A novel glutaminase isoform in mammalian tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Molecular regulation of lung endothelial glutamine synthetase expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Changes in aortic endothelial gene expressions and relaxation responses following chronic short-term insulin treatment in diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Glutamine and glutamate--their central role in cell metabolism and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Serine and glycine metabolism in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Genomic approach to identify factors that drive the formation of three-dimensional structures by EA.hy926 endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Nitric oxide synthase inhibition promotes endothelium-dependent vasodilatation and the antihypertensive effect of L-serine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

L-Serine lowers while glycine increases blood pressure in chronic L-NAME-treated and spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

L-Leucine and NO-mediated cardiovascular function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Mitochondrial production of superoxide anions and its relationship to the antimycin insensitive respiration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Generation of reactive oxygen species by the mitochondrial electron transport chain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Mitochondrial reactive oxygen species-mediated signaling in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2017.01.001

10.1016/J.VPH.2017.01.001

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

28082117